Long-acting FSH versus daily FSH for women undergoing assisted reproduction

Cochrane Database of Systematic Reviews

Volumn 2015, Issue 7, 2015, Pages

  Pouwer, Annefloor W ^a   Farquhar, Cindy ^b   Kremer, Jan A M ^c  

^a RIJNSTATE HOSPITAL   (Netherlands)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CORIFOLLITROPIN ALFA; FOLLITROPIN; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; LONG ACTING DRUG; DELAYED RELEASE FORMULATION; FOLLICLE STIMULATING HORMONE, HUMAN, WITH HCG C-TERMINAL PEPTIDE; HORMONE; LUTEINIZING HORMONE; RECOMBINANT PROTEIN;

BIRTH RATE; CONGENITAL MALFORMATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; DRUG SAFETY; ECTOPIC PREGNANCY; FOLLITROPIN BLOOD LEVEL; HUMAN; INFERTILITY THERAPY; INTRACYTOPLASMIC SPERM INJECTION; LOW DRUG DOSE; OVARY HYPERSTIMULATION; PREGNANCY RATE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REPRODUCTIVE SUCCESS; REVIEW; SPONTANEOUS ABORTION; SUBFERTILITY; SYSTEMATIC REVIEW; TREATMENT OUTCOME; ADMINISTRATION AND DOSAGE; ADULT; DELAYED RELEASE FORMULATION; FEMALE; FERTILIZATION IN VITRO; LIVE BIRTH; META ANALYSIS; OVULATION INDUCTION; PREGNANCY; PROCEDURES;

ADULT; DELAYED-ACTION PREPARATIONS; FEMALE; FERTILIZATION IN VITRO; FOLLICLE STIMULATING HORMONE; FOLLICLE STIMULATING HORMONE, HUMAN; HORMONES; HUMANS; LIVE BIRTH; LUTEINIZING HORMONE; OVULATION INDUCTION; PREGNANCY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECOMBINANT PROTEINS; SPERM INJECTIONS, INTRACYTOPLASMIC;

EID: 84957410492     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD009577.pub3     Document Type: Review

References (75)

1. Devroey P, Fauser BC, Platteau P, Beckers NG, Dhont M, Mannaerts BM. Induction of multiple follicular development by a single dose of long-acting recombinant follicle-stimulating hormone (FSH-CTP, corifollitropin alfa) for controlled ovarian stimulation before in vitro fertilization. Journal of Clinical Endocrinology and Metabolism May;89(5):2062-70.
2. NCT00702195. Pregnancy and neonatal follow-up of ongoing pregnancies established during phase II clinical trials for the development of Org 36286 (corifollitropin alfa). clinicaltrials.gov/show/NCT00702195 (accessed 18 June 2008).
3. NCT00702195. Pregnancy and neonatal follow-up of ongoing pregnancies established during phase II clinical trials for the development of Org 36286 (corifollitropin alfa). www.clinicalstudyresults.org (accessed 27 May 2009).
4. NCT00702806. A phase III, open-label, prospective, randomized, comparative clinical trial to investigate the appropriate dose of a single injection of Org 36286 (corifollitropin alfa) to initiate multiple follicular growth in a controlled ovarian hyperstimulation protocol for IVF or IVF/ICSI. clinicaltrials.gov/show/NCT00702806 (accessed 18 June 2008).
5. NCT00702806. A phase III, open-label, prospective, randomized, comparative clinical trial to investigate the appropriate dose of a single injection of Org 36286 (corifollitropin alfa) to initiate multiple follicular growth in a controlled ovarian hyperstimulation protocol for IVF or IVF/ICSI. www.clinicalstudyresults.org (accessed 11 February 2008).
6. Behr B, Heijnen E. Corifollitropin alfa versus recombinant FSH treatment for COS in a GnRH antagonist protocol: equal efficacy in terms of oocyte and embryo quality. Human Reproduction, European Society of Human Reproduction and Embryology, ESHRE 25th Annual Meeting; 2009 June 28-July 1 2009; Amsterdam, The Netherlands. 2009.
7. Bonduelle M, Mannaerts B, Leader A, Bergh C, Passier D, Devroey P. Prospective follow-up of 838 fetuses conceived after ovarian stimulation with corifollitropin alfa: comparative and overall neonatal outcome. Human Reproduction 2012;27(7):2177-85.
8. Boostanfar R, Devroey P, Oberye J, Mannaerts B. No difference in the cumulative pregnancy rates or live birth rates when comparing corifollitropin alfa with daily rFSH treatment for COS. Human Reproduction. Abstracts of the 26th Annual Meeting of ESHRE; 2010 June 27-30; Rome. 2010; Vol. 25 Suppl 1(6):i47 Abstract no. O-119.
9. Boostanfar R, Mannarts B, Witjes H, Devroey P. International differences in IVF live birth rates and ongoing pregnancy rates following ovarian stimulation with corifollitropin alfa or recombinant FSH. Fertility and Sterility, Annual Meeting of the American Society for Reproductive Medicine. 2011 Oct 15-19; Orlando 2011;96(Suppl 3):174.
10. Devroey P, Boostanfar R, Koper NP, Mannaerts BM, Ijzerman-Boon PC, Fauser BC, ENGAGE Investigators. Erratum: A double-blind, non-inferiority RCT comparing corifollitropin alfa and recombinant FSH during the first seven days of ovarian stimulation using a GnRH antagonist protocol. Human Reproduction 2014;29(5):1116-1120.
11. Devroey P, Boostanfar R, Koper NP, Mannaerts BMJL, Ijzerman-Boon PC, Fauser BC, ENGAGE Investigators. A double-blind, non-inferiority RCT comparing corifollitropin alfa and recombinant FSH during the first seven days of ovarian stimulation using a GnRH antagonist protocol. Human Reproduction 2009;24(12):3063-72.
12. Fatemi HM, Doody K, Witjes H, Mannaerts B. A high ovarian response does not compromise the change of pregnancy. Human Reproduction, 27th Annual Meeting of the European Society of Human Reproduction and Embryology, ESHRE. Stockholm, Sweden, 2011; Vol. 26, suppl 1:i319 Abstract no. P-510.
13. Fauser BC, Alper MM, Ledger W, Schoolcraft WB, Zandvliet A, Mannaerts BM, Engage Investigators. Pharmacokinetics and follicular dynamics of corifollitropin alfa versus recombinant FSH during ovarian stimulation for IVF. Reproductive BioMedicine Online 2010;21(5):593-601.
14. Fernandez Sanchez M, Koper N. Equally high ongoing pregnancy rates with corifollitropin alfa and recombinant FSH irrespective of variations in ART procedures. Human Reproduction, Abstracts of the 26th Annual Meeting of ESHRE; 2009 June 28-July 1; Amsterdam, The Netherlands. 2009; Vol. 24 Suppl 1:i2 O-005 Oral.
15. Hillensjo T, Yeko T, Witjes H, Elbers J, Devroey P. Does treatment flexibility affect clinical outcome of either corifollitropin alfa or daily regimens?. Human Reproduction, 27th Annual Meeting of the European Society of Human Reproduction and Embryology, ESHRE. Stockholm, Sweden, 2011; Vol. 26, issue suppl 1:i303-4 Abstract no. P468.
16. Leader A, Pang S, Witjes H, Gordon K, Devroey P. Reduction of daily rFSH dose from stimulation day 8 onward in a corifollitropin alfa or rFSH treatment regimen does not compromise clinical outcome. Human Reproduction, 27th Annual Meeting of the European Society of Human Reproduction and Embryology, ESHRE. Stockholm, Sweden, 2011:i302 Abstract no. P-465.
17. NCT00698800. A phase III, non-inferiority clinical trial to investigate the efficacy and safety of a single injection of 150 μg Org 36286 (corifollitropin alfa) to induce multifollicular development for ovarian stimulation using daily recombinant FSH as reference. clinicaltrials.gov/show/NCT00698800 (accessed 11 June 2008).
18. NCT00698800. A phase III, randomised, double-blind, active-controlled, non-inferiority clinical trial to investigate the efficacy and safety of a single injection of 150 μg Org 36286 (corifollitropin alfa) to induce multifollicular development for ovarian stimulation using daily recombinant FSH as reference. www.clinicalstudyresults.org (accessed 11 July 2008).
19. NCT00702273. Follow-up protocol to collect the outcome of frozen-thawed embryo transfer cycles after cryopreservation of embryos in clinical trial 38819. clinicaltrials.gov/show/NCT00702273 (accessed 18 June 2008).
20. NCT00702273. Follow-up protocol to collect the outcome of frozen-thawed embryo transfer cycles after cryopreservation of embryos in clinical trial 38819. www.clinicalstudyresults.org (accessed 16 February 2010).
21. NCT00703014. Pregnancy and neonatal follow-up of ongoing pregnancies established after controlled ovarian stimulation in Clinical Trial 38819 (P05787) for ORG 36286 (Corifollitropin alfa). www.clinicalstudyresults.org (accessed 7 July 2009).
22. NCT00703014. Pregnancy and neonatal follow-up of ongoing pregnancies established after controlled ovarian stimulation in Clinical Trial 38819 for ORG 36286 (Corifollitropin alfa). clinicaltrials.gov/show/NCT00703014 (accessed 18 June 2008).
23. Bonduelle M, Mannaerts B, Leader A, Bergh C, Passier D, Devroey P. Prospective follow-up of 838 fetuses conceived after ovarian stimulation with corifollitropin alfa: comparative and overall neonatal outcome. Human Reproduction 2012;27(7):2177-85.
24. Corifollitropin alfa Ensure Study Group: Obruca A, Schenk M, Tews G, Mardesic T, Mrazek M, Meinertz H, et al. Corifollitropin alfa for ovarian stimulation in IVF: a randomized trial in lower-body-weight women. Reproductive BioMedicine Online 2010;21(1):66-76.
25. Hillenjso T, Von Mauw E. A comparison of corifollitropin vs. recombinant FSH in a GnRH antagonist protocol for controlled ovarian stimulation in women weighing 60 kg or less. Human Reproduction. European Society of Human Reproduction and Embryology, ESHRE 25th Annual Meeting; 2009 June 28-July 1; Amsterdam. 2009; Vol. 24 Suppl 1:i2.
26. NCT00702546. Follow-up protocol to collect the outcome of frozen-thawed embryo transfer cycles after cryopreservation of embryos in clinical trial 107012. clinicaltrials.gov/show/NCT00702546 (accessed 18 June 2008).
27. NCT00702546. Follow-up protocol to collect the outcome of frozen-thawed embryo transfer cycles after cryopreservation of embryos in clinical trial 107012 (P05711). www.clinicalstudyresults.org (accessed November 2009).
28. NCT00702624. Pregnancy and neonatal follow-up of ongoing pregnancies established after controlled ovarian stimulation in clinical trial 107012 for the development of Org 36286 (corifollitropin alfa). clinicaltrials.gov/show/NCT00702624 (accessed 18 June 2008).
29. NCT00702624. Pregnancy and neonatal follow-up of ongoing pregnancies established after controlled ovarian stimulation in clinical trial 107012 for the development of Org 36286 (corifollitropin alfa) (107014/P05710). www.clinicalstudyresults.org (accessed 9 June 2009).
30. NCT00702845. A phase III, equivalence clinical trial to investigate the efficacy and safety of a single injection of 100 μg Org 36286 (Corifollitropin alfa) to induce multifollicular development for ovarian stimulation using daily recombinant FSH as reference. clinicaltrials.gov/show/NCT00702845 (accessed 18 June 2008).
31. NCT00702845. A phase III, randomized, double-blind, active-controlled, equivalence clinical trial to investigate the efficacy and safety of a single injection of 100 μg Org 36286 (Corifollitropin alfa) to induce multifollicular development for controlled ovarian stimulation (COS) using daily recombinant FSH (rFSH) as a reference. www.clinicalstudyresults.org (accessed 11 July 2008).
32. Corifollitropin Alfa Dose-finding Study Group: Abyholm T, Anderson AN, Balen AH, Braat DDM, Devroey P, D'Hooge TH, et al. A randomized dose-response trial of a single injection of corifollitropin alfa to sustain multifollicular growth during controlled ovarian stimulation. Human Reproduction 2008;23(11):2484-92.
33. NCT005982088. A phase 2, open label, randomized trial to investigate the dose-response relationship of a single injection or Org 36286 (corifollitropin alfa) to initiate multiple follicular growth in a controlled ovarian hyperstimulation protocol for IVF or ICSI. clinicaltrials.gov/show/NCT005982088 (accessed 10 January 2008).
34. NCT005982088. A phase 2, open label, randomized trial to investigate the dose-response relationship of a single injection or Org 36286 (corifollitropin alfa) to initiate multiple follicular growth in a controlled ovarian hyperstimulation protocol for IVF or ICSI. www.clinicalstudyresults.org (accessed 11 July 2008).
35. NCT00702988. Pregnancy and neonatal follow-up of ongoing pregnancies established during a previous clinical trial for the development of Org 36286 (corifollitropin alfa) (38827/P06056). www.clinicalstudyresults.org (accessed 28 May 2009).
36. NCT00702988. Pregnancy and neonatal follow-up of ongoing pregnancies established during clinical trial 38826 for the development of Org 36286 (corifollitropin alfa). clinicaltrials.gov/show/NCT00702988 (accessed 18 June 2008).
37. Boostanfar R, Mannaerts B, Pang S, Fernandez-Sanchez M, Witjes H, Devroey P, Engage Investigators. A comparison of live birth rates and cumulative ongoing pregnancy rates between Europe and North America after ovarian stimulation with corifollitropin alfa or recombinant follicle-stimulating hormone. Fertility and Sterility 2012;97(6):1351-8.
38. Boostanfar R, Mannaerts B, Witjes H, Devroey P. International differences in IVF live birth rates and cumulative ongoing pregnancy rates following ovarian stimulation with corifollitropin alfa or recombinant FSH. Fertility and Sterility 2011;1:S174.
39. Boostanfar R, Yeko T, Shapiro B, Elbers J, Witjes H, Mannaerts B. A large double-blind efficacy and safety trial of corifollitropin alfa versus daily recombinant FSH in women 35 to 42 years of age undergoing ovarian stimulation prior to IVF or ICSI (pursue trial). Fertility and Sterility 2012;98(Suppl 1):S34.
40. NCT01144416. A Phase III, Randomized, Double-blind, Active-controlled, Non-inferiority Trial to Investigate the Efficacy and Safety of a single injection of SCH 900962 (Corifollitropin alfa) to Induce Multifollicular Development for Controlled Ovarian Stimulation (COS) Using Daily Recombinant FSH (recFSH) as a Reference in Women aged 35-42 Years (P06029). clinicaltrials.gov/show/NCT01144416 (accessed 11 June 2010).
41. NCT01144416. Efficacy and safety study of a single injection of SCH 900962 versus daily recFSH injections in women undergoing controlled ovarian stimulation (study P06029 AM1) (PURSUE). clinicaltrials.gov/show/NCT01144416 (accessed 11 November 2013).
42. Stegmann B, Bonduelle M, Gordon K, Witjes H, Verweij P. Incidence of congenital malformations after ovarian stimulation with corifollitropin alfa or recombinant FSH: Data from 3 randomized controlled trials. Fertility and Sterility 2013;100(3):S59.
43. NCT01319695. Corifollitropin alfa versus recombinant follicle stimulating hormone (FSH) in ovarian stimulation of women undergoing in vitro fertilisation. clinicaltrials.gov/show/NCT01319695 (accessed 8 March 2011).
44. Sioulas V, Siristatidis C, Chrelias C, Alexiou E, Vrantza T, Kassanos D. Corifollitropin alfa vs. recombinant follicle stimulating hormone in ovarian stimulation of women undergoing in vitro fertilization: Preliminary results. Fertility and Sterility. 2011; Vol. 96 Suppl:S181 P-252.
45. Balen AH, Mulders AG, Fauser BC, Schoot BC, Renier MA, Devroey P, et al. Pharmacodynamics of a single low dose of long-acting recombinant follicle-stimulating hormone (FSH-carboxy terminal peptide, corifollitropin alfa) in women with World Health Organization group II anovulatory infertility. Journal of Clinical Endocrinology and Metabolism 2004;89(12):6297-304.
46. Croxtall JD, McKeage K. Corifollitropin alfa: a review of its use in controlled ovarian stimulation for assisted reproduction. BioDrugs 2011;25(4):243-54.
47. de Lartigue J. Corifollitropin alfa: a new option to treat female infertility. Drugs of Today 2011;47(8):583-90.
48. Fatemi HM, Oberyé J, Popovic-Todorovic B, Witjes H, Mannaerts B, Devroey P. Corifollitropin alfa in a long GnRH agonist protocol: proof of concept trial. Fertility and Sterility 2010;94(5):1922-4.
49. Leader A, Devroey P, Witjes H, Gordon K. Corifollitropin alfa or rFSH treatment flexibility options for controlled ovarian stimulation: a post hoc analysis of the Engage trial. Reproductive Biology and Endocrinology 2013;11:52.
50. Ledger W, Zandvliet A, Mannaerts B. On behalf on the ENGAGE/ENSURE investigators: Two doses of corifollitropin alfa allow for similar exposure and ovarian response in patients weighing ≤60 kg and >60 kg. Molecular Human Reproduction 2009;24(Suppl 1):i114.
51. Loutradis D, Vlismas A, Drakakis P. Corifollitropin alfa: a novel long-acting recombinant follicle-stimulating hormone agonist for controlled ovarian stimulation. Women's Health 2010;6(5):655-64.
52. Mahmoud Youssef MA, van Wely M, Aboulfoutouh I, El-Khyat W, van der Veen F, Al-Inany H. Is there a place for corifollitropin alfa in IVF/ICSI cycles? A systematic review and meta-analysis. Fertility and Sterility 2012;97(4):876-85.
53. Norman RJ, Zegers-Hochschild F, Salle BS, Elbers J, Heijnen E, Marintcheva-Petrova M, et al. Repeated ovarian stimulation with corifollitropin alfa in patients in a GnRH antagonist protocol: no concern for immunogenicity. Human Reproduction 2011;26(8):2200-8.
54. Prados N, Pellicer A, Fernandez-Sanchez M. Corifollitropin alfa: A new recombinant FSH gonadotropin analogue. Expert Review of Obstetrics and Gynecology 2011;6(4):395-402.
55. Rombauts L, Talmor A. Corifollitropin alfa for female infertility. Expert Opinion on Biological Therapy 2012;12(1):107-12.
56. Seyhan A, Baris A. The role of corifollitropin alfa in controlled ovarian stimulation for IVF in combination with GnRH antagonist. International Journal of Women's Health 2011;3:243-55.
57. Talmor A, McLachlan V, Osianlis T, Sorby KL, Lutjen P. Is longer better? The long and short of it - a matched case control study of long and short acting follicle stimulating hormone. Fertility and Sterility 2013;100(Supplement 3):S17.
58. Al-Inany HG, Youssef MAFM, Aboulghar M, Broekmans FJ, Sterrenburg MD, Smit JG, et al. Gonadotrophin-releasing hormone antagonists for assisted reproductive technology. Cochrane Database of Systematic Reviews 2011, Issue 5. [DOI: 10.1002/14651858.CD001750.pub3]
59. de Greef R, Zandvliet AS, de Haan AFJ, Ijzerman-Boon PCI, Marintcheva-Petrova M, Mannaerts BMJL. Dose selection of corifollitropin alfa by modeling and simulation in controlled ovarian stimulation. Clinical Pharmacology and Therapeutics 2010;88(1):79-87.
60. Devroey P, Boostanfar R, Koper NP, Mannaerts BMJL, IJzerman-Boon PC, Fauser BCJM, the ENGAGE Investigators. A double-blind, non-inferiority RCT comparing corifollitropin alfa and recombinant FSH during the first seven days of ovarian stimulation using a GnRH antagonist protocol. Human Reproduction 2009;24(12):3063-72.
61. Duijkers IJ, Klipping C, Boerrigter PJ, Machielsen CS, De Bie JJ, Voortman G. Single dose pharmacokinetics and effects on follicular growth and serum hormones of a long-acting recombinant FSH preparation (FSH-CTP) in healthy pituitary-suppressed females. Human Reproduction 2002;17(8):1987-93.
62. Evers JLH. Female subfertility. Lancet 2002;360(9327):151-9.
63. Fauser BC, Mannaerts BM, Devroey P, Leader A, Boime I, Baird DT. Advances in recombinant DNA technology: corifollitropin alfa, a hybrid molecule with sustained follicle-stimulating activity and reduced injection frequency. Human Reproduction Update 2009;15(3):309-21.
64. Gnoth C, Godehardt E, Frank-Herrmann P, Friol K, Tigges J, Freundl G. Definition and prevalence of subfertility and infertility. Human Reproduction 2005;20(5):1144-7.
65. Heineman MJ, Evers JLH, Massuger LFAG, Steegers EAP. Obstetrie en Gynaecology. De voortplanting van de mens. Amsterdam: Elsevier Gezondheidszorg, 2007.
66. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
67. Kovacs G. How to Improve your ART Success Rates. An Evidence-Based Review of Adjuncts to IVF. Cambridge: Cambridge University Press, 2011.
68. Maheshwari A, Gibreel A, Siristatidis CS, Bhattacharya S. Gonadotrophin-releasing hormone agonist protocols for pituitary suppression in assisted reproduction. Cochrane Database of Systematic Reviews 2011, Issue 8. [DOI: 10.1002/14651858.CD006919.pub3]
69. Farquhar C, Clarke J, Lethaby A, Thomas J, Proctor M, Barlow D, et al. Cochrane Menstrual Disorders and Subfertility Group, About The Cochrane Collaboration (Cochrane Review Groups (CRGs)). Available at www.thecochranelibrary.com 2008, issue 4.
70. The Nordic Cochrane Centre, the Cochrane Collaboration. Review Manager (RevMan). 5.3. Copenhagen: The Nordic Cochrane Centre, the Cochrane Collaboration, 2014.
71. Schröder AK, Katalinic A, Diedrich K, Ludwig M. Cumulative pregnancy rates and drop-out rates in a German IVF programme: 4102 cycles in 2130 patients. Reproductive Biomedicine Online 2004;8(5):600-6.
72. Tarlatzis BC, Kolibianakis EM. GnRH agonists vs antagonists. Best Practice & Research. Clinical Obstetrics and Gynaecology 2007;21(1):57-65.
73. Tur-Kaspa I, Fauser B. The use of GnRH agonist in IVF protocols. IVF Worldwide website accessed 20 May 2015:http://www.ivf-worldwide.com/survey/the-use-of-gnrh-agonist-in-ivf-protocols/results-the-use-of-gnrh-agonist-in-ivf-protocols.html.
74. Pouwer AW, Farquhar C, Kremer JA. Long-acting FSH versus daily FSH for women undergoing assisted reproduction. Cochrane Database of Systematic Reviews 2012, Issue 2.
75. Pouwer AW, Farquhar C, Kremer JA. Long-acting FSH versus daily FSH for women undergoing assisted reproduction. Cochrane Database of Systematic Reviews 2012, Issue 6. [DOI: 10.1002/14651858.CD009577.pub2]